NCT05914675: An ongoing trial by Institute of Hematology & Blood Diseases Hospital, China
This trial is ongoing. It must report results 2 weeks, 1 day from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05914675 |
|---|---|
| Title | Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After HLA-haploidentical Hematopoietic Stem Cell Transplantation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 1, 2023 |
| Completion date | Dec. 31, 2024 |
| Required reporting date | Dec. 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |